Stock Update (NYSE:LLY): FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

[PR Newswire] – Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination . . . → Read More: Stock Update (NYSE:LLY): FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection) Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union Stock Update: Eli Lilly & Company (NYSE:LLY) – Ready to go? The importance of advance planning: Lilly Diabetes and the American College of Endocrinology (ACE) help people with diabetes prep for emergencies Market Update (NYSE:LLY): Lilly Declares Second-Quarter 2014 Dividend